AstraZeneca's SGLT2 inhibitor, Farxiga, is now ...

...the subject of a phase III clinical trial testing its use against the novel coronavirus. About 900 severe COVID-19 patients at greater risk of cardiovascular, renal and kidney complications in both the U.S. and Europe will receive the drug. For the treatment of type 2 diabetes, Farxiga currently holds preferred status for 32% of covered lives in the U.S., growing to 58% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 4/27/20